Chase Pharmaceuticals Corporation
USPTO PatentsView assignee record - 13 granted patents across 3 technology areas, recorded in grant years 2015–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Chase ranks #20,912 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 3 technology areas.
- #20,912
- of 49,997 US assignees by volume
- 11th percentile
- by Innovation Score (22.7/100)
- 12.5
- avg claims per patent
- -82%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R20912 · US Corporation #20,912 · 13 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 13 grants
- MID-PACK #20,912/49,997
- PHOTO-FINISH Cellzome
- CPC-NARROW A61P · 3 areas
- INNOV-THIN 22.7/100
- CLAIMS-RICH 12.5 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -82% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Cellzome Limited (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Chase’s 22.7 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Chase
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Anko Food Machine · near 23
Anko Food Machine · near
23 score
- Chase Pharmaceuticals · this assignee 23
Chase Pharmaceuticals · this assignee
23 score
- Hyundai Pharm · near 23
Hyundai Pharm · near
23 score
- Guangdong Bestek… · near 23
Guangdong Bestek… · near
23 score
- Pacific Scientific… · near 23
Pacific Scientific… · near
23 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Chase's Innovation Score is 22.7/100 (11th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Chase?
Each dot is one of Chase’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Chase’s own 12.5 claims/patent is ABOVE the 10.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Chase's grants concentrate
Chase Pharmaceuticals Corporation is a focused PatentsView assignee: 3 CPC subclasses with 92.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (4 grants) versus a trough of 1 in 2016. By volume, Chase sits between Cellzome Limited and Cheveux Corporation.
Who files at Chase's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Cellzome
Cellzome Limited
13 patents
- Centogene
Centogene GmbH
13 patents
- Centriq Technology
Centriq Technology, Inc.
13 patents
- Changshu Institut…
Changshu Institute of Technology
13 patents
- Chauvet & Sons
Chauvet & Sons, LLC
13 patents
- Chelsio Communica…
Chelsio Communications, Inc.
13 patents
- Chembio Diagnosti…
Chembio Diagnostic Systems, Inc.
13 patents
- Cheveux
Cheveux Corporation
13 patents
- Chase Pharmaceuti… ◀
Chase Pharmaceuticals Corporation
13 patents
What this shows Chase holds 13 patents at rank #20,942, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Chase
By rank, the assignees closest to #20,942 in granted patent volume.
- Cellzome Limited #20,938 · 13 patents
- Centogene GmbH #20,939 · 13 patents
- Centriq Technology, Inc. #20,940 · 13 patents
- Changshu Institute of Technology #20,941 · 13 patents
- Chauvet & Sons, LLC #20,943 · 13 patents
- Chelsio Communications, Inc. #20,944 · 13 patents
- Chembio Diagnostic Systems, Inc. #20,945 · 13 patents
- Cheveux Corporation #20,946 · 13 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Chase's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Chase, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Chase ranks #1,593 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (23 here).
Chase's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
23 11th percentile higher than 11% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 15.4% |
| 2016 | 1 | 7.7% |
| 2017 | 2 | 15.4% |
| 2018 | 4 | 30.8% |
| 2019 | 2 | 15.4% |
| 2020 | 2 | 15.4% |
Which technologies does Chase Pharmaceuticals Corporation patent most?
Top 3 of 3 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Chase Pharmaceuticals Corporation's patent record in context - here's where to go next.
- Chase Pharmaceuticals Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.3% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #20,912 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Chase Pharmaceuticals Corporation against Cellzome Limited, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 22.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.